VLP Peanut for Peanut Allergy (PROTECT Trial)

"This clinical trial is recruiting 58 volunteers aged 18-50 years to participate, of whom must be in good physical health and have a confirmed peanut allergy. Participants need to provide informed consent and also meet the following requirements: no history of allergies or intolerance towards peanuts; non-atopic with no clinically significant co-morbidity such as asthma or rhinitis; female subjects who are not of childbearing potential (or females of childbearing potential who comply with contraceptive protocols); lack of sensitivity to peanut allergen verified via SPT using whole peanut extract."

"Affirmative. According to the details featured on clinicaltrials.gov, this medical trial is actively recruiting participants with a post date of October 1st 2022 and an edit date of October 6th 2022. 58 volunteers will be recruited from 2 sites for inclusion in the study."

"Our team at Power assigned Part A - Group A1 a score of 1 on our safety scale due to the preliminary nature of this Phase 1 trial, which has demonstrated limited efficacy and data regarding its protection against harm."

"This clinical trial is open to individuals 18 through 50 years of age. However, there are other studies that focus on those younger and older than the eligibility limits stated here--85 trials for minors and 156 for seniors."

"The primary objectives of this clinical trial monitored across 11 and 15 weeks respectively are to assess the occurrence and severity of Adverse Events (AEs) both locally and systemically. Secondary goals include measuring levels of fatigue, fever symptoms, as well as alterations in serum chemistry such as Alanine aminotransferase (ALT)."

"Affirmative. According to clinicaltrials.gov, the study is actively enrolling participants and has recorded two updates since its initial posting on October 1st 2022. A total of 58 patients need to be recruited from 2 different medical facilities."